Date post: | 03-Jan-2016 |
Category: |
Documents |
Upload: | victoria-doyle |
View: | 217 times |
Download: | 0 times |
eliminated from the body
It is the process by which
a drug or metabolite is
1Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
o Passive glomerular filtration
o Active tubular secretion in proximal tubules
o Passive tubular reabsorption.
2Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
Factors affecting renal excretion:
1-Glomerular filtration rate:
D
• Free • Water soluble • Low molecular weight
Filtered
3Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
Acidification of urine• vitamin C • NH4Cl
weak basebase drugs
2-Change in urinary pH
B+
B+
B+B+
B+
B+B+
Ionized
e.g. amphetamine
In AcidicAcidic medium
Excretion
4Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
Alkalinization of urine
weak AcidicAcidic drugs
2-Change in urinary pH
Ionized
In AlkalineAlkaline medium
Excretion
e.g. aspirin
A-A-A-A-
A-A-A-
NaHCO3
5Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
oIodides
oRifampicin
oSalicylates
Morphin
e
Tetracycline
Streptomycin
6Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
Portal v.
Bile
Ampicillin
Rifampicin
Biliary infection
Morphine
Enterohepatic circulation
7Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
3-Sweat: e.g., rifampicin (red color), vitamin B1.
4-Lungs: e.g., gases and volatile anesthetics.
5-Milk: Morphine Amphetamine Chloramphenicol Oral anticoagulants
8Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
It is the study of the:
Their mechanisms of action
Biological & therapeutic effects of drugs
10Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
RIntracellular
5. Cytotoxic action
Cell membrane
Nucleus
ion
2. selective passage of ions
XY → X +Y
E
Z
4. Metabolic pathway
1. Specific receptors
3. Enzyme
13
Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
E
Rev
Action on enzyme
Irrev
Stimulation Inhibition
Reversible
• short lasting
• e.g: Neostigmine
Cholinesterase
Irreversible
long-lasting (new enzyme synthesis )
e.g:
Organophsphrous compounds
E
E 14
Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
R
Intracellular
Cell membrane
Nucleus
Action on Specific receptors
RR
Bind specifically with a ligand:
• Neurotransmitter
• Drug
• Hormone
Biological response
ligand
15Prof.DR.AL SAYED ZAKI-BMC-
SAUDIA ARABIA
R
Nucleus
Biological response
ligand
Affinity =tendency to bind receptors
Efficacy =
Potency = how much drug is required to elicit a response.
16Prof.DR.AL SAYED ZAKI-BMC-
SAUDIA ARABIA
Agonists
R
ligand
• Affinity
• Efficacy
• Rapid dissociation rate
initiate changes
Antagonists • Affinity
R
ligand
• No efficacy
without initiating change
• slow dissociation rate
• Prevent action of agonist
ligand
17
Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
Competitive antagonism
R
antag
Ag
Ag
Ag
R
antag
Ag
Ag
Ag
Non-Competitive antagonism
Displaced by an
excess agonist Not displaced by an
excess agonist 18Prof.DR.AL SAYED ZAKI-BMC-
SAUDIA ARABIA
Partial agonists
Stimulate and block receptors
Affinity
Efficacy (less than full agonist)
Moderate dissociation rate
19Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
Inverse agonists •Produce effects opposite to that of agonist
•Benzodiazepines
•Agonists of Bz receptors
• Sedation, • Muscle relaxation • Anxiolytic action
•Inverse agonists of the Bz receptors
•Carbolines
• Convulsions • Anxiety.
20Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
1 (Age:Newborn infants especially premature are
more susceptible to drugs due to:
Underdevelopment of microsomal enzymes
Low plasma protein and low binding capacity
Reduced excretory function
Immaturity of blood brain barrier 22Prof.DR.AL SAYED ZAKI-BMC-
SAUDIA ARABIA
In infants use:
Clark's formula = adult dose x weight in kg
70
1 (Age:
23Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
•Children require small dose than adults
• In children use
Young's formula = adult dose x Age in years
Age +12
•They may metabolize some drugs more rapid
&so may need high dose of digitalis
1 (Age:
24Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
between 60-70 years
Elderly:
3/4 of adult dose
above 70 years ½the dose.
This is due to :
• Ageing of liver microsomal enzymes
• Underweight
•Reduced renal function
1 (Age:
25Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
2 (Body weight and surface area :
• The bigger the body weight the larger the dose
The increase in weight due to :
Oedema
Or Fat
Is not taken into consideration
26Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
In obese patients :
Dose of fat soluble drugs
Dose of water soluble drugs .
Surface area is more accurate parameter for dose calculation
27Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
2 (Sex:
need smaller dose than
This is due toThis is due to : :
Fat content
Enzyme inhibiting effect of female sex hormones
Enzyme inducing effect of male sex hormone 28Prof.DR.AL SAYED ZAKI-BMC-
SAUDIA ARABIA
During menstruation avoid : salicylates and castor oil.
During pregnancy avoid :
teratogenic drugs,
cathartics and uterine stimulants
During lactation avoid: chloramphenicol,
oral anticoagulantsphenolphthalein
2 (Sex:
29Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
3 (Route of administration:
I.V sublingual & inhalation
S.C I.M. oral >>> >Affect the dose:
I.V dose less than oral.
30Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
Magnesium sulphate:
• Orally is purgative
• Rectally is dehydrating agent
• I.V. it is anticonvulsions &
antagonizes Ca++
Affect the Action:
3 (Route of administration:
31Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
4) Drugs intolerance = supersensitivity
= hypersusceptibility:
Exaggerated action to normal dose of a drug
it may be due to:
• Decrease clearance of drug
or
• Upregulation of receptors.
dose
32Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
5(Tolerance:
Failure of response to the usual dose of a drug.
It may be:
1 .Congenital:
a) Racial:
b) Species:
c) Individual variation
2 .Acquired:
33Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
2 .Acquired Tolerance:
e.g:.
• Morphine,
Reversible
It may develop to some actions only & not to all actions
•Ethyl alcohol
• Nitrates, •Ephedrine
34Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
Special types of tolerance:
1) Tachyphylaxis e.g:
ephedrine on B.P.
2) Cross tolerance
(tolerance between related drugs)
e.g:
between ethyl alcohol & general anaesthesia.
35Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
Variation in drug response may be due to:
3. Number or
function of receptors
R
D
Variation in:
1 .Drug concentration
DD
D2 .Concentration of
endogenous transmitters
RR
36Prof.DR.AL SAYED ZAKI-BMC-
SAUDIA ARABIA
6 (Hypersensitivity (allergic) reaction:
D
Hapten
Immune response
D Does not occur on first exposure
Not dependent on dose
37Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
7) Idiosyncrasy = pharmacogenetics:
Abnormal reaction to drug due to: genetic
or enzyme defect:
o Succinylcholine apnea cholinesterase enzyme
o Malignant hyperthermia with
succinylcholine or halothane
38Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
7) Idiosyncrasy = pharmacogenetics:
o Anaemia & methemoglobinemia
G-6-PD
slow isoniazid acetylatoro Peripheral neuritis with
39Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
8 (Drug dependence:
Habituation :
Emotional or psychological
dependence on the drug
when stopped
Emotional distress
40Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
Addiction
Psychic craving for and physical
dependence on the drug
when stopped
severe withdrawal reaction
8 (Drug dependence:
41Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
9 (Pathological State:
Aspirin lowers fever temperature to normal,
but no effect on normal one.
42Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
10 (Cummulation:
Rate of drug administration > elimination
e,g, digitalis and guanethidine
43Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
11 (Emotional State (Placebo effect):
•Placebo are inert dosage forms which produce
their effect psychologically.
•They are used in testing new drugs
44Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
12 (Drug Combinations:
a. Addition or summation:
b. Synergism :
c. Potentiation:
d. Antagonism:
1 (Physiological
2 (Chemical
3 (Pharmacological
45Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
Toxicity of Drugs
Adverse (unwanted) drug effects
A) Unpredictable
1- Allergy (hypersensitivity reaction)
2- Idiosyncrasy.
B) Predictable
46Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
B) Predictable:
1- Overdose toxicity.
2- Teratogenic effects
3- Iatrogenic drugs
4- Long-acting sulphonamides can produce
jaundice in premature babies.
47Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
5- Blood dyscrasias by chloramphenicol,
6- Carcinogenic effect, e.g. smoking and radiation.
7- Hepatic toxicity, e.g., halothane.
8- Nephrotoxicity by: sulphonamides, aminoglycosides, phenacetin.
9- Nerve damage, e.g.: streptomycin can produce 8th cranial nerve damage
48Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
10 -Secondary effects, e.g:.
prolonged use of broad spectrum antibiotic
• superinfection &
• Vit. B & K deficiency.
49Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
11-Intolerance.
12-Drug dependence and addiction.
13-Drug interactions.
50Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
Therapeutic dose:
the average adult dose required
to produce a therapeutic effect.
52Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
Lethal dose:
dose that produces death
Maximal tolerated dose:
largest safe dose that can be taken.
53Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
Loading dose :
the dose given at the onset of therapy to
achieve rapid increase in
plasma drug concentration to reach Css
within therapeutic range.
54Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
Maintenance dose :
It is the dose needed to keep
the plasma drug concentration constant
at the steady state
i.e. to compensate for drug loss
in between doses.55Prof.DR.AL SAYED ZAKI-BMC-
SAUDIA ARABIA
Therapeutic index :
LD50/ED50
LD50 (median lethal dose): minimum dose that produces death
in 50% of experimental animals.
ED50 (median effective dose):
dose that produces
a certain pharmacological effect
in 50% of experimental animals.
it is measure for safety of drugs
56
Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
Plasma half life of a drug (t ½):
24
6
12
18
Drug concentration in Plasma
Time
Decline by
one half
=4 hours ?
58Prof.DR.AL SAYED ZAKI-BMC-
SAUDIA ARABIA
Plasma half life of a drug (t ½):
• It depends on drug clearance
• Half-life (t1/2) is important to indicate
the time required to attain steady state
• It is a measure for drug elimination
59Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
Types of drug elimination kinetics
First order kinetics:
a constant proportion of drug is
absorbed, metabolized or eliminated
depending on the drug
concentration
60Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
Types of drug elimination kinetics
Zero order kinetics:
where a constant number of
moles are absorbed or eliminated
irrespective of the total amount present.
61Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
First order kinetics
Rate of the process
≠α the amount of drug
t ½ is constant
Linear disappearance curve if log dose is used
Zero order kinetics
Rate of the process
the amount of drug
t ½ increases with dose
Non-linear disappearance curve if log dose is used
62Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
Methods to prolong duration of action of drugs
11--Delay absorptionDelay absorption
a) add vasoconstriction e.g adrenaline to local anaesthetics.
b) Add oil e.g. vasopressin.
63Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
e) Use of sustained release (SR) or controlled release (CR)
or timed release (TR)
c) Use of suspensions e.g. protamine zinc insulin.
d) S.C pellet implantation e.g. contraceptives
long acting preparations
64Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA
3-Decrease metabolism
4-Delay renal excretion:
probenecid to decrease penicillin excretion.
2-Increase protein binding:
e.g. sulfonamides.
e.g. enzyme inhibitors
65Prof.DR.AL SAYED ZAKI-BMC-SAUDIA ARABIA